Search results

Filters
Close
ADDED DATE
Added date
TOPICS Please select
WATCH / LISTEN / READ TIME
Lipid-lowering Therapies and Lp(a)
Author(s): Stephen Nicholls , Adam J Nelson Added: 1 month ago

Prevention & Chronic Conditions
Lp(a) and Atherosclerosis
Author(s): Annalisa Filtz , Leandro Slipczuk , Martha Gulati Added: 3 months ago

Prevention & Chronic Conditions
AHA 25: Lp(a) and ASCVD: Translating Causal Evidence into Clinical Practice
Author(s): Michelle O'Donoghue Added: 7 months ago
AHA Scientific Sessions 2025 - Dr Michelle O'Donoghue (Brigham and Women's Hospital, US) joins us to discuss the evolving understanding of the causal relationship between elevated lipoprotein(a) and atherosclerotic cardiovascular disease, and what this means for risk stratification and management strategies in clinical practice.Dr O'Donoghue begins by highlighting the importance for clinicians to… View more

Cardiovascular Kidney Metabolic

Prevention & Chronic Conditions
ESC 25: LipoaScreen: Cascade Screening for LP(a)
Author(s): Jonas Brinck Added: 9 months ago
ESC Congress 2025 - Cascade screening proves to be an effective tool to identify more patients with elevated LP(a) levels.Dr Jonas Brinck (Karolinska Institute, SE) joins us to discuss findings from the LipoaScreen study, evaluating cascade screening for elevated lipoprotein(a) in relatives of patients with atherosclerotic coronary artery disease.This prospective study examined whether elevated… View more

Imaging & Diagnostics

Prevention & Chronic Conditions
Pelacarsen Cuts Lipoprotein Apheresis Need in CVD
Added: 3 months ago Source:  Radcliffe CVRM
For patients with elevated lipoprotein(a) [Lp(a)] and established cardiovascular disease (CVD), weekly lipoprotein apheresis (LA) is the only approved treatment, but it represents a significant burden. The Lp(a)FRONTIERS APHERESIS trial investigated whether the investigational therapy pelacarsen could reduce the need for this invasive procedure.¹Mechanism of ActionPelacarsen is a hepatocyte… View more

Cardiovascular Kidney Metabolic
ACC 2025: The ALPACA Phase 2 Trial
Author(s): Steven E Nissen Added: 1 year ago
ACC 2025 - 540-day follow up of lepodisiran in patients with elevated lipoprotein(a) (Lp(A)) shows the extended duration of action of lepodisiran will allow infrequent dosing in the ongoing cardiovascular outcome trial.Dr Steven Nissen (Cleveland Clinic, Cleveland, US) joins us onsite at ACC to discuss the ALPACA phase 2 trial (NCT05565742), investigating the safety and efficacy of lepodisiran,… View more

Prevention & Chronic Conditions
ANGPTL3 Gene Editing: Promise and Prudence
Author(s): Alberto Lorenzatti Added: 3 months ago

Prevention & Chronic Conditions
30th Annual Meeting of the ISCP
Author(s): María Salgado , Alberto Alen Andrés , Maria Fernández García , et al Added: 2 months ago

Inherited and Congenital Cardiac Conditions

Prevention & Chronic Conditions
Paolo Mulatero
Job title: Professor of Internal Medicine and Head of the Hypertension Unit
Prof Paolo Mulatero is Professor of Internal Medicine and Head of the Hypertension Unit, Department of Medical Sciences at the University of Turin, Turin, Italy. His main research interests include pathophysiology; clinical and molecular genetics of primary aldosteronism; biochemistry and genetics of 11b-hydroxylase and aldosterone synthase (CYP11B1 and CYP11B2) and their role in human… View more
Piotr Ponikowski
Research Area(s) / Expertise: Job title: Head of the Department of Heart Diseases
Piotr Ponikowski is Head of the Department of Heart Diseases, Wroclaw Medical University and Head of the Cardiology Department at the Center for Heart Diseases at 4th Military Hospital, Wroclaw, Poland. His research interests mainly include heart failure (HF), coronary artery disease and cardiac arrhythmias. He has been involved in numerous research projects, such as the benefits of physical… View more